Glofitamab in Relapsed/Refractory DLBCL: Fixed-Duration Therapy and CRS Timing

Dr. Chavez reviews glofitamab, the second bispecific antibody approved for relapsed/refractory DLBCL, and compares its pivotal data with those of epcoritamab. He notes that the trial enrolled a similarly heavily pretreated population, including patients with prior CAR T-cell therapy and autologous stem cell transplant, with complete response rates comparable to those seen with epcoritamab. Dr. Chavez outlines key differences in administration: glofitamab is given intravenously after obinutuzumab pretreatment, which is intended to reduce CRS risk, followed by step-up dosing and then a set number of treatment cycles. He highlights this fixed-duration schedule as a key advantage. Both physicians note that CRS and ICANS rates appear comparable between the agents, but timing differs, with CRS most often occurring after the first glofitamab dose. Dr. Phillips emphasizes teaching fellows and care teams when to anticipate CRS with each agent.